Transfusion-Transmitted Viruses Study (TTVS) - Catalog
-
Name
Transfusion-Transmitted Viruses Study (TTVS)
-
Accession Number
HLB01910909a
-
Acronym
TTVS
-
Related studies(NANB-TAH) Natural History Study of Non-A, Non-B Post-Transfusion Hepatitis (NANB-TAH)
-
BSI Study IDs
TTV
-
Is public use dataset
False
-
Keywords
-
Ingestion Status---------
-
Has Study Datasets
False
-
Has Specimens
True
-
Specimen ID TypeCoded
-
Study Website
-
The Framingham Heart Study Group requires that the requestor must obtain full or expedited IRB/Ethics Committee review and approval to obtain these data. Waivers or a determination that the research is exempt from ethical regulations do not suffice.
False
-
Clinical Trial URLsN/A
-
Study typeEpidemiology Study
-
Collection TypeOpen BioLINCC Study
-
Cohort typeAdult
-
Interventions
-
Study Open Date (Data)
None
-
Study Open Date (Specimens)
2009-10-01
-
Date materials available
2009-09-03
-
Last updated
2023-02-07
-
Study period
1974-1980
-
Study Contacts
-
NHLBI Division
DBDR
-
ClassificationTransfusion Medicine
-
HIV study classificationHIV-Related
-
COVID study classificationnon-COVID
-
Pre-Website # of Specimens Shipped
13146
-
# of Returned Specimens
0
-
Primary Publication URLs
N/A
-
Commercial use data restrictionsNot Applicable (Specimens Only)
-
Data restrictions based on area of researchNot Applicable (Specimens Only)
-
Commercial use specimen restrictionsNo
-
Non-genetic use specimen restrictions based on area of useYes
-
Genetic use of specimens allowed?Yes
-
Genetic use area of research restrictionsYes
-
Specific Consent Restrictions
Consent for both genetic and non-genetic use of biospecimens is restricted to studies involving transfusion safety.
-
ConditionsNANB Hepatitis
-
Objectives
To establish a repository of specimens collected from prospectively identified cases of non-A, non-B (NANB) hepatitis after blood transfusion. The major intentions were to determine the incidence of that occurrence, identify the characteristics of the donors associated with the event, and have a resource available to compare laboratory donor screening methods during the study and in subsequent years following completion of the study.
-
Background
From July 1974 through June 1980, the TTVS group prospectively identified cases of NANB hepatitis in a cohort of 1,533 transfused patients hospitalized short-term for various routine operative procedures. The TTVS collection has been used in a variety of studies, such as the evaluation and validation of Hepatitis C Virus (HCV) immunoassays in screening blood donors (1). In addition, specimens have been requested to evaluate poorly characterized hepatotropic viruses, transmissibility of new viruses (hepatitis G, HHV-8) by transfusion, and the dynamics of HBV/HCV viral replication and seroconversion in recipients.
-
Participants
Serum specimens from 5,655 blood donors were collected from 4 participating blood centers distributed across the US. 3,121 patients were consented to participate in a study of viral hepatitis after blood transfusion. The majority of patients were scheduled for elective surgery. Of these subjects, 1,533 subsequently received blood transfusions. Both transfusion recipients and control subjects that did not require transfusion were observed and blood was collected prior to surgery or pre-transfusion and again during visits at 2-3 week intervals during the first 6 months following the transfusion episode and again between 8-10 months.
A subset of this cohort was subsequently recruited into the Natural History Study of Non-A, Non-B Post Transfusion Hepatitis (NANB-TAH) that also has data and biospecimens available. Subjects cannot be linked between these two studies.
-
Design
The collection originally consisted of aliquots of serum acquired at patient observation visits and from the collection agency for every donor to each TTVS recipient. These sera included the pre-transfusion or pre-surgical specimen, all interval blood draws from these patients and the non-transfused control patients, a specimen from the donor at the time of blood collection and in a subpopulation of donors a follow-up specimen from donors implicated in suspected cases of transfusion transmitted hepatitis and a matched set of non-implicated donors.
-
Conclusions
The TTVS collection provides sera from a large transfusion donor-recipient study in which an untransfused control population with reasonably matched characteristics and of adequate size is available.
-
Disease classification
-
Publications
- Mosley JW, et al. (1990) Non-A, non-B hepatitis and antibody to hepatitis C virus. JAMA 263(1):77-78.
-
Mat typesPlasma or Serum
Serum
-
Network
Please note that biospecimen availability is subject to review by the NHLBI, BioLINCC, and the NHLBI Biorepository. Certain biospecimens may not be made available for your request. Section 3.0 of the BioLINCC Handbook describes the components of the review process.
-
Material Types
-
General Freeze/Thaw Status
-
Visits (Vials)
12/06/2018
Serum Plasma or Serum Total Recipient Visit 1 11,046 993 12,039 Recipient Visit 2 6,255 21 6,276 Recipient Visit 3 12,464 33 12,497 Recipient Visit 4 11,094 88 11,182 Recipient Visit 5 7,067 296 7,363 Recipient Visit 6 9,369 778 10,147 Recipient Visit 7 5,888 203 6,091 Recipient Visit 8 6,881 289 7,170 Recipient Visit 9 9,126 700 9,826 Recipient Visit 10 6,350 248 6,598 Recipient Visit 11 7,275 309 7,584 Recipient Visit 12 7,601 595 8,196 Recipient Visit 13 3,945 170 4,115 Recipient Visit 14 1,816 51 1,867 Recipient Visit 15 1,071 28 1,099 Recipient Visit 16 765 20 785 Recipient Visit 17 677 13 690 Recipient Visit 18 553 14 567 Recipient Visit 19 509 8 517 Recipient Visit 20 407 7 414 Recipient Visit 21 329 3 332 Recipient Visit 22 247 5 252 Recipient Visit 23 193 0 193 Recipient Visit 24 198 2 200 Recipient Visit 25 156 1 157 Recipient Visit 26 96 0 96 Recipient Visit 27 84 0 84 Recipient Visit 28 80 0 80 Recipient Visit 29 80 0 80 Recipient Visit 30 59 0 59 Recipient Visit 31 60 0 60 Recipient Visit 32 42 0 42 Recipient Visit 33 30 0 30 Recipient Visit 34 30 0 30 Recipient Visit 35 28 0 28 Recipient Visit 36 23 0 23 Recipient Visit 37 21 0 21 Recipient Visit 38 12 0 12 Recipient Visit 39 26 0 26 Recipient Visit 40 21 0 21 Recipient Visit 41 13 0 13 Recipient Visit 42 14 0 14 Recipient Visit 43 18 0 18 Donor 1 12,372 1,302 13,674 Donor 2 10,330 1,036 11,366 Donor 3 6,747 599 7,346 Donor 4 5,188 423 5,611 Donor 5 3,745 297 4,042 Donor 6 2,696 217 2,913 Donor 7 1,812 147 1,959 Donor 8 1,178 107 1,285 Donor 9 800 68 868 Donor 10 485 35 520 Donor 11 357 33 390 Donor 12 229 20 249 Donor 13 122 11 133 Donor 14 69 4 73 Donor 15 14 3 17 Donor 17 1 0 1
Last Modified: Sept. 4, 2025, 1:47 p.m. -
Visits (Subjects)
12/06/2018
Serum Total number of subjects Average volume (ml) per subject Recipient Visit 1 1,506 3.88 Recipient Visit 2 1,505 4.54 Recipient Visit 3 1,511 4.20 Recipient Visit 4 1,508 4.28 Recipient Visit 5 1,504 4.43 Recipient Visit 6 1,515 4.35 Recipient Visit 7 1,506 4.49 Recipient Visit 8 1,509 4.51 Recipient Visit 9 1,497 4.31 Recipient Visit 10 1,478 4.49 Recipient Visit 11 1,430 4.36 Recipient Visit 12 1,313 4.17 Recipient Visit 13 1,004 4.30 Recipient Visit 14 389 4.02 Recipient Visit 15 206 3.72 Recipient Visit 16 144 3.71 Recipient Visit 17 115 3.57 Recipient Visit 18 98 3.48 Recipient Visit 19 84 3.75 Recipient Visit 20 70 3.81 Recipient Visit 21 61 3.60 Recipient Visit 22 42 3.50 Recipient Visit 23 38 3.40 Recipient Visit 24 35 3.44 Recipient Visit 25 27 3.22 Recipient Visit 26 22 2.50 Recipient Visit 27 20 3.06 Recipient Visit 28 15 3.08 Recipient Visit 29 14 2.68 Recipient Visit 30 13 2.68 Recipient Visit 31 12 2.71 Recipient Visit 32 8 2.63 Recipient Visit 33 6 2.71 Recipient Visit 34 5 2.84 Recipient Visit 35 4 2.86 Recipient Visit 36 3 3.37 Recipient Visit 37 3 3.18 Recipient Visit 38 3 2.50 Recipient Visit 39 3 2.12 Recipient Visit 40 3 2.50 Recipient Visit 41 2 3.88 Recipient Visit 42 3 1.92 Recipient Visit 43 2 3.38 Donor 1 1,513 4.55 Donor 2 1,248 4.62 Donor 3 818 4.38 Donor 4 609 4.47 Donor 5 447 4.45 Donor 6 327 4.28 Donor 7 227 4.29 Donor 8 152 4.18 Donor 9 104 4.11 Donor 10 68 4.06 Donor 11 49 4.26 Donor 12 30 4.23 Donor 13 16 4.00 Donor 14 10 3.51 Donor 15 3 4.17 Donor 17 1 2.50 Plasma or Serum Total number of subjects Average volume (ml) per subject Recipient Visit 1 985 0.22 Recipient Visit 2 21 0.25 Recipient Visit 3 32 0.26 Recipient Visit 4 85 0.24 Recipient Visit 5 293 0.25 Recipient Visit 6 773 0.26 Recipient Visit 7 203 0.25 Recipient Visit 8 289 0.25 Recipient Visit 9 696 0.26 Recipient Visit 10 247 0.24 Recipient Visit 11 305 0.24 Recipient Visit 12 591 0.24 Recipient Visit 13 165 0.23 Recipient Visit 14 49 0.24 Recipient Visit 15 27 0.22 Recipient Visit 16 19 0.21 Recipient Visit 17 13 0.21 Recipient Visit 18 14 0.19 Recipient Visit 19 8 0.18 Recipient Visit 20 7 0.19 Recipient Visit 21 3 0.20 Recipient Visit 22 5 0.17 Recipient Visit 24 2 0.15 Recipient Visit 25 1 0.05 Donor 1 939 0.23 Donor 2 770 0.23 Donor 3 474 0.23 Donor 4 334 0.23 Donor 5 253 0.22 Donor 6 180 0.23 Donor 7 126 0.23 Donor 8 90 0.21 Donor 9 58 0.21 Donor 10 32 0.20 Donor 11 31 0.21 Donor 12 18 0.22 Donor 13 11 0.20 Donor 14 4 0.24 Donor 15 3 0.23
Last Modified: Sept. 4, 2025, 1:47 p.m.